WO2004100986A3 - Utilisation pharmaceutique d'une substance inhibant l'enzyme adam 10 - Google Patents

Utilisation pharmaceutique d'une substance inhibant l'enzyme adam 10 Download PDF

Info

Publication number
WO2004100986A3
WO2004100986A3 PCT/GB2004/002098 GB2004002098W WO2004100986A3 WO 2004100986 A3 WO2004100986 A3 WO 2004100986A3 GB 2004002098 W GB2004002098 W GB 2004002098W WO 2004100986 A3 WO2004100986 A3 WO 2004100986A3
Authority
WO
WIPO (PCT)
Prior art keywords
adam
pharmaceutical use
inhibitory substance
ectodomain
shedding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2004/002098
Other languages
English (en)
Other versions
WO2004100986A2 (fr
Inventor
John Bird
Sheila Bridget Mcloughlin
Matthew Joseph Barnes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech R&D Ltd
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Publication of WO2004100986A2 publication Critical patent/WO2004100986A2/fr
Publication of WO2004100986A3 publication Critical patent/WO2004100986A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne l'utilisation d'une substance pouvant inhiber ADAM 10, une enzyme impliquée dans l'élimination de l'ectodomaine de CD23, pour produire un médicament servant à traiter des maladies allergiques parmi lesquelles figurent l'asthme, la dermatite atopique ainsi que la rhinite allergique.
PCT/GB2004/002098 2003-05-16 2004-05-13 Utilisation pharmaceutique d'une substance inhibant l'enzyme adam 10 Ceased WO2004100986A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0311228.1 2003-05-16
GBGB0311228.1A GB0311228D0 (en) 2003-05-16 2003-05-16 Assay

Publications (2)

Publication Number Publication Date
WO2004100986A2 WO2004100986A2 (fr) 2004-11-25
WO2004100986A3 true WO2004100986A3 (fr) 2005-01-13

Family

ID=9958169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/002098 Ceased WO2004100986A2 (fr) 2003-05-16 2004-05-13 Utilisation pharmaceutique d'une substance inhibant l'enzyme adam 10

Country Status (2)

Country Link
GB (1) GB0311228D0 (fr)
WO (1) WO2004100986A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2620022A1 (fr) * 2005-08-31 2007-03-08 Serentis Limited Utilisation d'un inhibiteur de l'aureolysine pour le traitement de maladies inflammatoires de la peau caracterisees par une colonisation par staphylococcus aureus
GB2453589A (en) 2007-10-12 2009-04-15 King S College London Protease inhibition
EP2637679A4 (fr) * 2010-11-09 2015-09-23 Univ Chicago Rôle d'adam10 et sa pertinence au plan pathologique et thérapeutique

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0921197A2 (fr) * 1997-08-25 1999-06-09 Smithkline Beecham Disintegrin-métalloprotéase humaine liée au gène KUZ de Drosophila
WO2000056871A2 (fr) * 1999-03-08 2000-09-28 Falk Fahrenholz CELLULES COEXPRIMANT UNE PROTEINE PRECURSEUR AMYLOIDE ET UNE α-SECRETASE, ET LEURS UTILISATIONS DANS DES METHODES D'ESSAI ET A DES FINS DE DIAGNOSTIC
WO2003051825A1 (fr) * 2001-12-14 2003-06-26 Exelixis, Inc. Inhibiteurs de l'adam-10 humaine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0921197A2 (fr) * 1997-08-25 1999-06-09 Smithkline Beecham Disintegrin-métalloprotéase humaine liée au gène KUZ de Drosophila
WO2000056871A2 (fr) * 1999-03-08 2000-09-28 Falk Fahrenholz CELLULES COEXPRIMANT UNE PROTEINE PRECURSEUR AMYLOIDE ET UNE α-SECRETASE, ET LEURS UTILISATIONS DANS DES METHODES D'ESSAI ET A DES FINS DE DIAGNOSTIC
WO2003051825A1 (fr) * 2001-12-14 2003-06-26 Exelixis, Inc. Inhibiteurs de l'adam-10 humaine

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AMOUR AUGUSTIN ET AL: "The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3", FEBS LETTERS, vol. 473, no. 3, 19 May 2000 (2000-05-19), pages 275 - 279, XP004337152, ISSN: 0014-5793 *
HERMANN P ET AL: "The vitronectin receptor and its associated CD47 molecule mediates proinflammatory cytokine synthesis in human monocytes by interaction with soluble CD23.", THE JOURNAL OF CELL BIOLOGY. 22 FEB 1999, vol. 144, no. 4, 22 February 1999 (1999-02-22), pages 767 - 775, XP002298911, ISSN: 0021-9525 *
MAROLEWSKI A E ET AL: "CD23 (FcepsilonRII) release from cell membranes is mediated by a membrane-bound metalloprotease.", THE BIOCHEMICAL JOURNAL. 1 AUG 1998, vol. 333 ( Pt 3), 1 August 1998 (1998-08-01), pages 573 - 579, XP002298908, ISSN: 0264-6021 *
PARKIN EDWARD T ET AL: "Structure-activity relationship of hydroxamate-based inhibitors on the secretases that cleave the amyloid precursor protein, angiotensin converting enzyme, CD23, and pro-tumor necrosis factor-alpha.", BIOCHEMISTRY. 16 APR 2002, vol. 41, no. 15, 16 April 2002 (2002-04-16), pages 4972 - 4981, XP002298909, ISSN: 0006-2960 *
SAWA MASAAKI ET AL: "New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.", JOURNAL OF MEDICINAL CHEMISTRY. 14 FEB 2002, vol. 45, no. 4, 14 February 2002 (2002-02-14), pages 919 - 929, XP002299083, ISSN: 0022-2623 *
SUTTON B J ET AL: "THE HUMAN IGE NETWORK", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 366, 2 December 1993 (1993-12-02), pages 421 - 428, XP000421323, ISSN: 0028-0836 *

Also Published As

Publication number Publication date
WO2004100986A2 (fr) 2004-11-25
GB0311228D0 (en) 2003-06-18

Similar Documents

Publication Publication Date Title
IL291162A (en) Isolated human rpe cells and their use for the treatment of retinal degenerative diseases
WO2007141796A3 (fr) Utilisations thérapeutiques d'inhibiteurs de rtp801l
EP2402443A3 (fr) Utilisations thérapeutiques d'inhibiteurs de rtp801
EP2319925A3 (fr) Utilisations thérapeutiques d'inhibiteurs du RTP801
WO2002020002A3 (fr) Methode de traitement des allergies
WO2002078766A3 (fr) Polytherapie
WO2005046603A3 (fr) Composes pyridiniques
IL230241A (en) Retinal history and methods of using them to treat visual irregularities
WO2008029276A8 (fr) Compositions et procédés de traitement d'une maladie ophtalmique
WO2005116088A3 (fr) Methodes et compositions pour traiter des maladies et des troubles associes a des cellules exprimant siglec-8
WO2003099217A3 (fr) Methodes de traitement d'infections bacteriennes et de maladies associees
AU2001249262A1 (en) Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof
AUPS017702A0 (en) Methods and compositions for the treatment of asthma and related disorders
WO2006055871A3 (fr) Traitement de la sclerose en plaques
WO2006085115A3 (fr) Utilisations therapeutiques d'extraits de tomate
AU2003260748A1 (en) Il-14 vaccine for the treatment of asthma and atopic disorders
AU2003904328A0 (en) Diagnosis and treatment of neurodegenerative disorders
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
WO2004100986A3 (fr) Utilisation pharmaceutique d'une substance inhibant l'enzyme adam 10
WO2005063757A3 (fr) Nouvelles formes cristallines de temozolomide
AU2002315485A1 (en) Compositions and methods for the treatment of body weight disorders, including obesity
PL376756A1 (pl) Zastosowanie S-10-hydroksy-10,11-dihydro-karbamazepiny do leczenia zaburzeń lękowych i chorób dwubiegunowych
WO2004112690A3 (fr) Derives de 2-aminobenzoyle
WO2007048097A3 (fr) Derives de l'androsterone et leur procede d'utilisation
TW200626167A (en) Sophorae Radix extract for prevention and treatment of respiratory diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase